Showing results (91-100 of 218) with videos related to
Sort By:
Pageof 22
Science Advances|November 23, 2022
Widespread hypertranscription in aggressive human cancersMatthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancersA Drilon, I Bergagnini, L Delasos, et al.Nature Communications|July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapyAkane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.Journal for Immunotherapy of Cancer|February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.Cancer Immunology Research|July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCFernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung AdenocarcinomasM C Pietanza, Matthew D Hellmann, John J Fiore, et al.Cancer Cell|June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.Pageof 22